Phosphatidylinositol 3-kinases (PI3Ks) are a group of lipid kinases that regulate signaling pathways involved in cell proliferation, adhesion, survival, and motility. Even though PIK3CA amplification and somatic mutation have been reported previously in various kinds of human cancers, the genetic change in PIK3CA in human breast cancer has not been clearly identified.
Methods
Fifteen breast cancer cell lines and 92 primary breast tumors (33 with matched normal tissue) were used to check somatic mutation and gene copy number of PIK3CA. For the somatic mutation study, we specifically checked exons 1, 9, and 20, which have been reported to be hot spots in colon cancer. For the analysis of the gene copy number, we used quantitative real-time PCR and fluorescence in situ hybridization. We also treated several breast cancer cells with the PIK3CA inhibitor LY294002 and compared the apoptosis status in cells with and without PIK3CA mutation.
Results
We identified a 20.6% (19 of 92) and 33.3% (5 of 15) PIK3CA somatic mutation frequency in primary breast tumors and cell lines, respectively. We also found that 8.7% (8 of 92) of the tumors harbored a gain of PIK3CA gene copy number. Only four cases in this study contained both an increase in the gene copy number and a somatic mutation. In addition, mutation of PIK3CA correlated with the status of Akt phosphorylation in some breast cancer cells and inhibition of PIK3CA-induced increased apoptosis in breast cancer cells with PIK3CA mutation.
Conclusion
Somatic mutation rather than a gain of gene copy number of PIK3CA is the frequent genetic alteration that contributes to human breast cancer progression. The frequent and clustered mutations within PIK3CA make it an attractive molecular marker for early detection and a promising therapeutic target in breast cancer.
The online version of this article (doi:10.1186/bcr1262) contains supplementary material, which is available to authorized users.
Authors' contributions
GW carried out PCR and sequencing reactions and prepared the manuscript. MX carried out primer design and PCR reactions. EM carried out real-time PCR reactions and prepared the manuscript. XH carried out FISH analysis. JW carried out apoptosis analysis. ZG carried out sequencing reactions. AC carried out sample preparation and real-time PCR. DG is the pathologist and carried out data analysis. SG coordinated FISH analysis. SS provided all breast cancer tissue and helped in designing the study. DS conceived of the study and participated in its design. BT coordinated all the studies. All authors read and approved the final manuscript.
Abkürzungen
BAC
bacterial artificial chromosome
DAPI
4',6-diamidino-2-phenylindole
FISH
fluorescence in situ hybridization
H & E
hematoxylin and eosin
PI3K
phosphatidylinositol 3-kinase.
Introduction
Phosphatidylinositol 3-kinases (PI3Ks) are a group of lipid kinases composed of 85-kDa and 110-kDa subunits. The 85-kDa subunit lacks PI3K activity and acts as adaptor, coupling the 110-kDa subunit (P110) to activated protein tyrosine kinases and generating second messengers by phosphorylating membrane inositol lipids at the D3 position. The resulting phosphatidylinositol derivatives then permit activation of downstream effectors that are involved in cell proliferation, survival, metabolism, cytoskeletal reorganization, and membrane trafficking [1, 2].
PIK3CA, the gene encoding the 110-kDa subunit of PI3K, was mapped to 3q26, an area amplified in various human cancers including ovarian, head and neck, breast, urinary tract, and cervical cancers [3‐5]. PIK3CA was specifically found to be amplified and overexpressed in ovarian and cervical cancer [6‐9]. The increased copy number of the PIK3CA gene is associated with increased PIK3CA transcription, P110-alpha protein expression, and PI3K activity in ovarian cancer [9]. Treatment with a PI3K inhibitor decreased proliferation and increased apoptosis, suggesting that PIK3CA has an important role in ovarian cancer. More recently, PIK3CA mutations were identified in different human cancers. In that report, PIK3CA was mutated in 32%, 27%, 25%, and 4% of colon, brain, gastric, and lung cancers, respectively. Only 12 cases of breast cancer were examined, of which one was found to harbor a mutation in PIK3CA [10].
Anzeige
In an effort to identify the genetic alterations of the PIK3CA gene in breast cancer, we determined the mutation frequency and the change in the gene copy number of PIK3CA in a set of primary breast tumors and breast cancer cell lines. We found a high frequency of these somatic alterations of PIK3CA gene in a large number of primary breast cancers. In addition, mutation of the PIK3CA gene correlated with the activation of Akt. Inhibition of PIK3CA induced significant apoptosis in cells with PIK3CA mutation.
Materials and methods
Breast cancer cell line and tumors
Of the breast cancer cell lines examined, MCF12A, Hs.578t, and MDA436 were kindly provided by Dr Nancy Davidson at Johns Hopkins University, and MDA-MB157, MDA-MB468, BT474, T47D, and UACC893 were kindly provided by Dr Fergus J Couch at Mayo Clinic. The other cell lines were obtained from the American Type Culture Collection. A total of 92 cases of breast tumor, including 33 paired primary invasive breast carcinomas and adjacent normal tissues (frozen tissue), were obtained from the Surgical Pathology archives of the Johns Hopkins Hospital, Baltimore, MD, USA, in accordance with the Institutional Review Board protocol and DNA was isolated using a standard phenol–chloroform protocol. Prof Saraswati Sukumar at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University provided isolated DNA. Each tumor used in this study was determined to contain greater than 70% tumor cells by H&E staining. Among these specimens, 3 were stage 1, 52 were stage 2, 22 were stage 3, and 4 were stage 4. Eleven were of uncharacteristic stage status. All of the tumors were high grade.
PCR, sequencing, and mutational analysis
Cell line and tumor DNA were isolated as standard protocol. The primers we used for PCR and sequencing were as follows. For exon 1: forward, CTCCACGACCATCATCAGG, reverse, GATTACGAAGGTATTGGTTTAGACAG, and sequencing primer, ACTTGATGCCCCCAAGAATC; for exon 9: forward, GATTGGTTCTTTCCTGTCTCTG, reverse, CCACAAATATCAATTTACAACCATTG, and sequencing primer, TTGCTTTTTCTGTAAATCATCTGTG; for exon 20: forward, TGGGGTAAAGGGAATCAAAAG, reverse, CCTATGCAATCGGTCTTTGC, and sequencing primer, TGACATTTGAGCAAAGACCTG. We used the same PCR conditions for all three exons. After incubation at 95°C for 5 min, two cycles of amplification were performed at the initial annealing temperature of 62°C, with a subsequent annealing temperature decrease of 2°C for every two cycles until 54°C. Twenty-five amplification cycles were then performed. After PCR reaction, samples were subjected to automated DNA sequencing using the ABI 377 Sequencer. The positive samples were confirmed by re-PCR and sequencing using the same primers and conditions.
Western blotting
To evaluate Akt phosphorylation status, MDA231, MD361, MCF7, BT20, BT474, and T47D cells were grown in appropriate medium and cell lysates were collected in SDS lysis buffer (cell signaling). Lysates were cleared of insoluble material by microcentrifugation at 15,800 g for 15 min at 4°C, and protein concentrations were determined (protein assay kit; Bio-Rad, Hercules, CA, USA). Approximately 50 μg of total protein from each sample was denatured in loading buffer for 10 min, electrophoresed through 10% polyacrylamide gels, and electroblotted to a nylon transfer membrane (Schleicher & Schuell, Bioscience, Keene, NH USA). The membrane was incubated overnight with primary antibody Akt ser473 (antirabbit, cell signaling), Akt (anti rabbit, Cell signaling) or β-actin (antimouse antibody; Sigma, St Louis, MO, USA) at 4°C. Then the membrane was washed three times in Tris-buffered saline with 0.1% Tween 20 at room temperature and incubated for 1 hour at room temperature with horseradish-peroxidase-labeled secondary antibody (goat antirabbit IgG; or goat antimouse IgG; Sigma). Signal detection was by horseradish peroxidase chemiluminescent reaction (ECL; Amersham).
Anzeige
Quantitative real-time PCR
For real-time PCR, specific primers and probes were designed using software from Applied Biosystems (Foster City, CA, USA) to amplify the PIK3CA and control β-actin (sequences are available on request). Using this combination and the protocol described by Mambo and colleagues [11], the samples were run in triplicate. Primers and probes to β-actin were run in parallel to standardize the input DNA (4 ng). Standard curves were developed using serial dilutions of DNA extracted from MCF12A. PCR amplifications were performed on an ABI 7900 TaqMan (Applied Biosystems) according to the manufacturer's protocol.
Fluorescence in situhybridization (FISH)
Bacterial artificial chromosome (BAC) clone RP11-466H15 for PIK3CA was obtained from Research Genetics (Invitrogen Corporation, Carlsbad, CA, USA). BAC DNA isolation was carried out using the standard laboratory protocol for phenol–chloroform extraction. The chromosome 3 α-satellite plasmid and BAC DNA were labeled directly in SpectrumOrange-dUTP® and SpectrumGreen-dUTP® (Vysis, Downers Grove, IL, USA), respectively, using the Vysis nick translation kit (Vysis) in accordance with the manufacturer's instructions. Slides were fixed using methanol:acetic acid (3:1), followed by pretreatment with RNase, and dual-color FISH was performed as described previously [12]. Slides were counterstained with 4',6-diamidino-2-phenylindole (DAPI; Sigma), mounted with antifade (Vysis), and stored at -20°C. At least 100 nuclei were evaluated for each sample. Analysis was carried out using an Olympus (New Hyde Park, NY, USA) BHS fluorescence microscope, and images were captured using a CytoVision Ultra (Applied Imaging, Santa Clara, CA, USA).
Apoptosis detection
We assessed cellular apoptosis using an Annexin V-FITC (fluorescein isothiocyanate) apoptosis detection kit (BD Biosciences, San Jose, CA, USA). Cells were cultured in 100-mm dishes until 50% confluent, serum-starved overnight, and then treated with LY294002, 3 μM and 10 μM, for 72 hours. Both detached and adherent cells were then collected and labeled with Annexin V-FITC and Propidium Iodide. The apoptosis was evaluated using FACScan (Becton Dickinson ImmunoSystems, Mountain View, CA, USA) flow cytometer.
Results
PIK3CAis frequently mutated in breast cancer cell lines and primary tumors
A previous report suggested that more than 80% of the mutations of the PIK3CA gene occur in three small clusters, namely in the p85 (exon 1), helical (exon 9) and kinase (exon 20) domains [10]. Based on this information, we sequenced exon 1, 9, and 20 in 15 breast cancer cell lines, 92 primary tumors, and 33 normal tissues. A total of five mutations were identified only in the 15 breast cancer cell lines (33.3%). No mutations were detected in the normal epithelial cell line MCF12A. Three of the mutations were identified in exon 9 and two were found in exon 20. No mutation was identified in exon 1. The BT20 cell line contained two different mutations, C1616G in exon 9 and A3140G in exon 20 (Fig. 1), corresponding to P539R and H1047R amino acid change, respectively.
Figure 1
Detection of somatic mutation of PIK3CA in breast cancer. In each case, the left sequence chromatogram was obtained from normal control and the right sequence chromatogram was obtained from tumor. Arrows indicate the location of missense mutations. The nucleotide and amino acid alterations are indicated on the left.
×
A total of 19 mutation cases (20.6%) were identified in 92 primary tumors. Six of the 19 mutations were identified in 33 tumor samples but not in their paired normal samples. This indicated that the identified mutations are somatic mutations. Thirteen of these 19 mutations were in exon 9, and 6 were in exon 20. No mutation was identified in exon 1 in any of the 92 tumors. As shown in Table 1, the E545K mutation in exon 9 and the H1047R mutation in exon 20 were the two most frequent mutations in both breast cancer cell lines and primary tumors.
Table 1
Somatic mutation of PIK3CA in breast cancer cell lines and primary tumors
Exon
Nucleotide
Amino acid
Functional domain
Cell lines
Tumors
Total
9
C1616G
P539R
Helical
1 (BT20)
1
9
G1624A
E542K
Helical
3
3
9
G1633A
E545K
Helical
2 (MDA361, MCF7)
8
10
9
A1634G
E545G
Helical
1
1
20
A3140G
H1047R
Kinase
2 (BT20, UACC893)
5
5
20
A3140T
H1047L
Kinase
1
No. with mutations
5
19
22
No. samples screened
15
92
Percent of cases with mutations
33.3
20.6
Gain of copy number of PIK3CAgene in primary breast cancer cell lines and tumors
To determine the PIK3CA gene copy number, we performed real-time quantitative PCR on 12 breast cancer cell lines, 92 primary tumors, and 33 normal controls. Standard curves for PIK3CA and β-actin amplification were generated using serially diluted MCF12A DNA, and showed linearity over the range used. Fig. 2a shows the standard curve for PIK3CA amplification with a slope of -4.044, while Fig. 2b shows the standard curve for β-actin amplification with a slope of -3.919. We did not observe any deletion of β-actin in the tumor samples. Most samples showed no difference in β-actin amplification between the paired tumor and a normal samples. A representative figure of β-actin amplification in a paired tumor and normal sample is shown in Fig. 2c. To evaluate the gene copy number in all samples, we set the cutoff line at 4 copies. Among the 33 cases with paired tissue, 8 (24.2%) showed a much higher gene copy number than normal controls (Fig. 3a). Only one case showed more than 4 copies. In a total of 92 cases of primary tumors, 8 (8.7%) had more than 4 copies, with the highest number being 7.8 copies (Fig. 3b). In addition, PIK3CA gene copy number was also determined in 12 breast cancer cell lines, and the MCF7, T47D, and BT474 cell lines had more than 4 copies (Fig. 3c). We also confirmed the gene copy number results of these 12 cell lines with FISH analysis. Representative FISH images are shown in Fig. 3d. Thus, our data of gene copy analysis indicates that gene amplification/gain of copy number of PIK3CA gene is not a frequent genetic alteration in breast cancer.
Figure 2
Typical real-time PCR curves generated for a cell line, a tumor, and normal tissue. Typical standard curves generated for (a) β-actin and (b)PIK3CA using serial diluted DNA from cell line MCF12A. (c) Representative real-time PCR curves for β-actin, generated using paired normal and tumor DNA from breast tissue of one individual. Each experiment was performed in triplicate and is shown by overlapping amplification curves. ΔRn = (Rn+) - (Rn-), where Rn+ is the fluorescence emission intensity of reporter/emission intensity of quencher at any time point, and Rn- is the initial emission intensity of reporter/emission intensity of quencher in the same reaction vessel before PCR amplification was initiated. Ct, cycle threshold.
Figure 3
Gain of PIK3CA gene copy number in breast cancer. (a)The change in the gene copy number of PIK3CA in 33 paired breast tissue samples. *Cases with significant change in gene copy number. The case number is indicated below the panel. (b) The change in the gene copy number of PIK3CA in 92 breast tumors and 33 normal controls. (c) Eight samples show more than 4 copies of PIK3CA. (d) The change in the gene copy number of PIK3CA in breast cancer cells using real-time PCR. Representative images of fluorescence in situ hybridization (FISH) analysis in various breast cancer cell lines. Green signals represent bacterial artificial chromosome (BAC) 466H15 probe. Red signals represent chromosome 3 centromere probe.
×
×
Biological effect of PIK3CAmutations in breast cancer
To determine whether the mutation of PIK3CA correlated with the activation of Akt (a downstream gene of PIK3 that mediates carcinogenic events such as proliferation), we performed western blot analysis to check the phosphorylation of Akt in several breast cancer cell lines. As shown in Fig. 4a, Akt phosphorylation was strongest in BT20 cells (which harbor two PIK3CA mutations) and MCF7 cells (which harbor PIK3CA mutation and high PIK3CA gene copy numbers). We also observed weak phosphorylation of Akt in MDA361 (which has one mutation) and in BT474 and T47D (no observable mutation but with high PIK3CA gene copy numbers). We did not observe phosphorylation of Akt in MDA231 (Fig. 4a) or in MCF12A and MDA157 cells (data not shown) that had no observable mutations and no copy number gain of PIK3CA. These data indicate that PIK3CA mutations might increase kinase activity and in turn activate the PI3K/AKT pathway.
Figure 4
Biological effect of PIK3CA mutations in breast cancer. (a) Phosphorylation (P) of Akt in breast cancer cells. Western blotting showed stronger phosphorylation of Akt in BT20 and MCF7 cells than in MDA 231, MDA361, BT474, or T47D. β-Actin was used as a protein loading control. (b) Summary of the fraction of apoptotic cell in three cell lines with different treatments (3 μM and 10 μM LY294002). [(c) Apoptosis measurement in which cells were stained with Annexin V-FITC and for DNA content with Propidium Iodide and analyzed using flow cytometry. Apoptotic cells appear as a discrete population with elevated FITC fluorescence. FITC, fluorescein isothiocyanate; SS, serum starvation
×
We further investigated the biological effects of PIK3CA mutation in breast cancer cell lines by treating breast cancer cells with or without PIK3CA mutation with the PIK3CA inhibitor LY294002. As shown in Table 1, MCF7 harbors one mutation at position E545K, and BT20 harbors two mutations, which are located at positions P539R and H1047R. These somatic mutations were recently shown to have oncogenic transforming activity [13]. As shown in Fig. 4b and 4c, the fractions of apoptotic cells at 72 hours after treatment with 3 μM and 10 μM LY294002 were increased in MCF7 and BT20 cells. In addition, 3 μM and 10 μM LY294002 did not induce further apoptosis in MDA157 cells (Fig. 4c) or MDA231 cells (data not shown), even though serum starvation alone can induce more than 50% apoptosis in MDA157 cells (Fig. 4c).
Anzeige
Discussion
This study describes two innovations. First, we show a 20.6% mutation rate of the PIK3CA gene in breast cancer, indicating that PIK3CA mutation is a frequent genetic alteration in breast cancer. The 8% mutation rate of PIK3CA in breast cancer, reported in a previous study, was underestimated [10], probably because of the smaller number of cases examined. Another possibility might be the grade status of the tumors used, as all of the tumors in our study were of high grade. It will be useful and interesting in the future to explore whether PIK3CA mutation is correlated with tumor grade status.
Second, CGH (comparative genomic hybridization) studies have shown that 3q26 is an amplified chromosome region in various cancers, including breast cancer [4, 5]. Unfortunately, it was not previously possible to identify the PIK3CA gene amplification pattern, because of the low resolution of the methods used. In our study, we used quantitative real-time PCR, a very sensitive and far more accurate technique [14, 15], to specifically quantitate the genomic copy number of PIK3CA not only in primary breast tumors but also in paired tissues. Our data showed that gene amplification or gain of PIK3CA copy number is not a frequent genetic alteration event. This suggests that gene amplification is not the main molecular mechanism in activating the PIK3/AKT-driven tumorigenesis pathway in breast cancer.
Even though a complex and heterogeneous set of genetic alterations, including gene amplification/gain of copy number, deletion, and mutation, were reported to be involved in the etiology of breast cancer [16, 17], our paper confirmed that gain of gene copy number and somatic mutation of one oncogene exist in parallel in breast cancer. Both amplification/gain of gene copy number and somatic mutation of PIK3CA have been shown to be associated with increased PI3K activity and might contribute to cancer through inhibition of apoptosis [6, 9]. Gene amplification/gain of gene copy is well accepted as a later event in tumor progression [18, 19], as is somatic mutation [10]. To determine the relation between somatic mutation and gain of gene copy number of PIK3CA gene in breast cancer, we integrated our mutation and gene copy number data. As shown in Table 2, 19 (20.6%) of 92 cases had a PIK3CA gene mutation and 4 cases did not harbor a mutation but showed a gain of gene copy number. Overall, a quarter (23 of 92) of all breast tumors examined had either a mutation or gain of copy number of the PIK3CA. In addition, 15 of 19 mutations were identified in tumors without gain of copy number of PIK3CA, suggesting that somatic mutations are a major contributory factor in the PIK3CA signaling pathway. Only four cases in the whole study had both a mutation and gain of copy number of PIK3CA. We did not observe a significant association between somatic mutation and gain of PIK3CA gene copy number in 92 cases of breast tumors (Table 2). We suggest that further studies using larger number of cases be undertaken in order to determine whether somatic mutation and gene amplification are independent genetic alterations in breast cancer.
Table 2
The relation of somatic mutation and gain of copy number of PIK3CA in breast cancer
Mutation-
Mutation+
Total
Gain+
4
4
8
Gain-
69
15
84
Total
73
19
92
Fisher exact test, P = 0.054.
Conclusion
The results from this study indicate that somatic mutation rather than gene amplification of PIK3CA is the main genetic alternation in breast cancer. The frequent and clustered mutations within PIK3CA make it an attractive molecular marker for early detection of breast cancer. In addition, the somatic mutations lead to activation of PIK3CA and also correlate with the activation of the PI3K/AKT pathway. Inhibition of PIK3CA can significantly induce apoptosis in cells with PIK3CA mutation. This suggests that PIK3CA might be a promising therapeutic target in breast cancer.
Anzeige
(During the writing of this manuscript, Bachman KE and colleagues published their results in Cancer Biology and Therapy [20]. They also reported more than 20% somatic mutations in breast cancer, a finding consistent with this study).
Acknowledgements
We thank Dr Nancy Davidson at Johns Hopkins University and Dr Fergus J Couch at Mayo Clinic for providing some breast cancer cell lines. This work was supported by the following grants: National Cancer Institute's Lung Cancer SPORE Grant No. CA 58184-01 and the National Institute of Dental and Craniofacial Research Grant No. RO1-DE 012588-0.
Authors' contributions
GW carried out PCR and sequencing reactions and prepared the manuscript. MX carried out primer design and PCR reactions. EM carried out real-time PCR reactions and prepared the manuscript. XH carried out FISH analysis. JW carried out apoptosis analysis. ZG carried out sequencing reactions. AC carried out sample preparation and real-time PCR. DG is the pathologist and carried out data analysis. SG coordinated FISH analysis. SS provided all breast cancer tissue and helped in designing the study. DS conceived of the study and participated in its design. BT coordinated all the studies. All authors read and approved the final manuscript.
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
verfasst von
Guojun Wu Mingzhao Xing Elizabeth Mambo Xin Huang Junwei Liu Zhongmin Guo Aditi Chatterjee David Goldenberg Susanne M Gollin Saraswati Sukumar Barry Trink David Sidransky
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
